These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2106765)

  • 1. Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol.
    Stason WB
    Am Heart J; 1990 Mar; 119(3 Pt 2):718-24; discussion 724. PubMed ID: 2106765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.
    van der Weijden T; Knottnerus JA; Ament AJ; Stoffers HE; Grol RP
    J Epidemiol Community Health; 1998 Sep; 52(9):586-94. PubMed ID: 10320860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
    Pharoah PD; Hollingworth W
    BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for cholesterol?
    Kerrigan P
    Practitioner; 1989 May; 233(1468):627. PubMed ID: 2513564
    [No Abstract]   [Full Text] [Related]  

  • 6. The economics of cholesterol lowering.
    Reckless JP
    Baillieres Clin Endocrinol Metab; 1990 Dec; 4(4):947-72. PubMed ID: 2128019
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness perspectives in coronary heart disease.
    Goldman L
    Am Heart J; 1990 Mar; 119(3 Pt 2):733-9; discussion 739-40. PubMed ID: 1968700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Benefits and costs of early detection and treatment of hypercholesterolemia].
    Laaser U
    Z Kardiol; 1994; 83 Suppl 6():163-7. PubMed ID: 7863690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacoeconomic benefits of cholesterol reduction.
    Gonzalez ER
    Am J Manag Care; 1998 Feb; 4(2):223-30. PubMed ID: 10178493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.
    Montagne O; Vedel I; Durand-Zaleski I
    Clin Ther; 1999 Nov; 21(11):2027-35. PubMed ID: 10890271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of preventive medicine. Screening in adults.
    Meade TW
    Ciba Found Symp; 1985; 110():69-87. PubMed ID: 3921322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.
    Hay JW; Wittels EH; Gotto AM
    Am J Cardiol; 1991 Apr; 67(9):789-96. PubMed ID: 1901436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifetime health and economic benefits of weight loss among obese persons.
    Oster G; Thompson D; Edelsberg J; Bird AP; Colditz GA
    Am J Public Health; 1999 Oct; 89(10):1536-42. PubMed ID: 10511836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of interventions to prevent or treat coronary heart disease.
    Weinstein MC; Stason WB
    Annu Rev Public Health; 1985; 6():41-63. PubMed ID: 2859868
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1998 Sep; 142(38):2096-101. PubMed ID: 9856223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
    Rubió PP
    Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.
    Talbert RL
    Am J Manag Care; 2002 Sep; 8(12 Suppl):S301-7. PubMed ID: 12240701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.